on Xlife Sciences AG (isin : CH0461929603)
Xlife Sciences AG: General Meeting Success and Future Growth
On June 24, 2025, Xlife Sciences AG held its Annual General Meeting where all proposals by the Board were approved. A significant 55.42% of the share capital was represented, highlighting shareholders' trust. The company reported advances in its AI-based diagnostics commercialization and preclinical projects in 2024.
CEO Oliver R. Baumann highlighted VERAXA Biotech’s progress towards a NASDAQ listing with an estimated valuation of USD 1.64 billion. This is a testament to Xlife Sciences' model of translating innovations into market-ready solutions. Additionally, Dr. Frank Plöger will spearhead the company's expansion into the U.S. market, focusing on partnerships and project development.
The portfolio now includes Firstgene Life Sciences GmbH, a developer of precision gene therapies, expanding Xlife’s capacity in fighting liver cancer. A Financial report for 2025 is scheduled for September 23.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Xlife Sciences AG news